Author: jezzabellemente

Statistics show 1 in 3 women will be diagnosed with cancer in their lifetime – timely advancements in research and treatment are crucial to women’s health

DALLAS, Dec 8 (Bernama-BUSINESS WIRE) — Mary Kay Inc., the world’s No. 1 direct selling skin care and color cosmetics brand¹ and its company-sponsored foundations, including the Mary Kay Ash Foundation in the U.S., continue to provide unwavering support to women’s cancer research through funding a variety of research programs and projects, awarding grants to world renowned scientists, and facilitating clinical trials, all in the name of finding a cure.

This press release features multimedia. View the full release here: 
https://www.businesswire.com/news/home/20231207401297/en/

Mary Kay recently hosted a virtual meeting between Dr. Joyce O’Shaughnessy, Celebrating Women Endowed Chair in Breast Cancer Research at Baylor University Medical Center and Chair, Breast Cancer Research at U.S. Oncology based in Dallas, Texas, and Dr. Eva Ciruelos, Breast Cancer Unit Coordinator, University Hospital and HM Hospitals and Chair, SOLTI Group on Breast Cancer Research, and FERO Foundation grant recipient supported by Mary Kay Spain, based in Madrid, Spain. Both lead their own research teams in their respective home countries focused on investigating the rare and aggressive form of cancer in women: triple negative metastatic breast cancer (TNBC). Despite being separated by thousands of miles, the two go way back – they have collaborated for years on TNBC research in their fight to find solutions and a cure for this devastating disease.

The two leading researchers and experts in their respective fields sat down to discuss the importance of global scientific collaboration, in which they stressed the urgency for researchers worldwide to share their findings and advances to pool results.

”It is not a matter of having the best idea, but of arriving together to obtain the best treatment for each patient, and this is something that must permeate the medical, clinical, and pharmaceutical industries. The incidence of breast cancer in women is seeing an upward trend in the world, and today we can say that 1 in 3 women will be diagnosed with cancer in their lifetime²,” said Dr. O’Shaughnessy.

”Without continuous collaboration among all the experts, it would be impossible to arrive at specific diagnoses,” commented Dr. Ciruelos. ”It is vital to follow up each patient’s treatment in a personalized way; only then will we be able to detect why the same treatment for people with similar characteristics works for some, but not for others.”

They confirmed their frustration with the differences and inconsistencies they see in access to therapies, drugs, and treatments within various countries and called for unity in offering more consistent treatment for all patients regardless of their place of living. The two researchers also agreed that it is challenging to find time to fully dedicate themselves to cancer research as they have to deal with funding challenges and expressed their gratitude to their sponsors, including the Mary Kay Ash Foundation and Fero Foundation who make their life-saving work possible.

Dr. O’Shaughnessy added, “In 1985, we were terribly frustrated by the lack of therapeutic options for women with cancer. Today, we are seeing great advances on this front and I’m very optimistic for the success of the next generation of researchers.”

Through the funding of cancer research projects by the Mary Kay Ash Foundation in the United States and Mary Kay Spain’s grant award to FERO Foundation in Spain, Dr. O’Shaughnessy and Dr. Ciruelos have been able to continue collaborating on their life’s work. Mary Kay is at the forefront of women’s cancer research, supporting groundbreaking research led by women for women. Mary Kay is committed to helping researchers around the world by supporting translational research (research that links laboratory research directly to the patient), clinical trials aimed at improving the detection, prognosis, and treatment of women’s cancers, as well as organizations that support cancer research, such as the FERO Foundation in Spain.

Watch their full conversation on the Mary Kay Global YouTube channel.

About Mary Kay

Then. Now. Always. One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty brand in Texas in 1963 with one goal: to enrich women’s lives. That dream has blossomed into a global company with millions of independent sales force members in more than 35 countries. For 60 years, the Mary Kay opportunity has empowered women to define their own futures through education, mentorship, advocacy, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in preserving our planet for future generations, protecting women impacted by cancer and domestic abuse, and encouraging youth to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn, or follow us on X (formerly known as Twitter).

¹ ”Source Euromonitor International Limited; Beauty and Personal Care 2023 Edition, value sales at RSP, 2022 data.”

² American Cancer Society. https://www.cancer.org/cancer/types/breast-cancer/about/how-common-is-breast-cancer.html

View source version on businesswire.com: 
https://www.businesswire.com/news/home/20231207401297/en/

Contact

Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com

Source : Mary Kay Inc.

–BERNAMA

SHENZHEN, China, Dec. 8, 2023 /Xinhua-AsiaNet/–

Green development is a crucial lens for the world to observe China’s high-quality development. At the recent Qianhai Global Investment Promotion and Talent Conference, Qianhai introduced the new Six Agglomerations. It is believed that environmentally-friendly enterprises and investments in green industries will see more development opportunities in Qianhai.

Green development is accelerating in Qianhai, making the area a new epitome of China’s low-carbon development. The Qianhai Cooperation Zone has thoroughly promoted green buildings in regional construction and development, focusing on the intensive and extensive development of green buildings, according to Authority of Qianhai Shenzhen-Hong Kong Modern Service Industry Cooperation Zone. In that way, it has been seeking a sustainable urban development model under high-intensity development.

Qianhai has established a cross-industry and cross-sectoral management and control mechanism across the chain in the field of green buildings, which has presented remarkable results. According to the latest data, a total of 48 projects in Qianhai have been awarded the Green Building Design Label, with a cumulative increase of 6.907 million square meters of green building area. Compared to cities such as Beijing and Shanghai, Qianhai has set itself as a frontrunner in terms of the new area density and growth rate of green buildings.

At the beginning of the year, the Ministry of Ecology and Environment of China released the latest typical cases of comprehensive planning and policies on its official website, which included the Construction of a Large-scale Demonstration Area for High-Star Green Buildings launched by the China (Guangdong) Pilot Free Trade Zone Shenzhen Qianhai Shekou Area.

Promoting green building development is just one way for Qianhai to accelerate regional low-carbon construction. The construction of a regional centralized cooling system is another key approach to building Qianhai into an energy-efficient and environmentally-friendly urban area with low energy consumption, low pollution, and low emissions.

Shenzhen Qianhai Energy Technology Development Co., Ltd., a subsidiary of Shenzhen Qianhai Development Investment Holding Co., Ltd., undertakes the investment, construction, and operation of the regional centralized cooling system. The representative of the company stated in an interview, “The construction of Qianhai’s centralized cooling system has offered a very meaningful ‘Qianhai model’ that is worth learning from and promoting for the development of green buildings.”

The Guangdong-Hong Kong-Macao Greater Bay Area (GBA) serves as a pivotal gateway connecting domestic and international markets. In the GBA, ports constitute a key component for Qianhai to connect with the world and a focal point of Qianhai’s low-carbon development. Mawan Smart Port in Qianhai has incorporated green, low-carbon, and smart elements, utilizing green and low-carbon systems to achieve green development and comprehensive environmental protection. It is estimated that the port can reduce carbon emissions by 90% per year compared to traditional ports, including a reduction of approximately 1350 tons of nitrogen dioxide, 450 tons of carbon monoxide, and 15 tons of sulfur dioxide emissions.

Industry insiders predict that Qianhai’s green development practices will set an impactful model for the GBA and even other parts of China. It is believed that in the low-carbon transition, Qianhai will lead the way and catalyze the GBA to enhance the overall quality of its green development.

Source: Authority of Qianhai Shenzhen-Hong Kong Modern Service Industry Cooperation Zone 

KUALA LUMPUR, Dec 6 (Bernama) — More than 1.5 million visitors have visited the Auckland Museum, New Zealand to see Barbara and Peter, the world’s first display of an adult male and female Tyrannosaurus rex (T. rex) pairing, which has run for a year, will draw to a close on Dec 10.

Given that New Zealand itself has a population of just 5.1 million inhabitants, the visitors who came to see the two T.rex dinosaurs are unprecedented, with numbers equivalent to a third of the population of the country.

Auckland Museum Chief Executive Officer, David Reeves said Barbara and Peter have provided a once-in-a-lifetime, educational experience for many, many thousands of school children.

“It has been a joy to see people’s reactions as they encounter these magnificent specimens for the first time,” he said in a statement.

T. rex fossils are extremely rare, with only about 20 of them on display in museums worldwide, and these were the first T. rex exhibits in the Southern Hemisphere, while there is no T. rex on permanent exhibit in the Middle East, the whole of Asia, Africa or Latin America, with only four T. rex on display in Europe.

Female T. rex specimens are rarer still, with Barbara representing only the third ever pregnant T. rex dinosaur skeleton to be discovered. Barbara is 44.7 per cent complete, making her the eighth most complete T. rex in the world, measuring an impressive 11.7 metres (m) long and 3.4m high.

Close viewing of the T.rex reveals some of the incredible anatomical features of one of the largest land predators of all time and offers the ability to inspect injuries that pathological findings revealed, specifically an injury to Barbara’s leg, likely to have been caused by another T. rex.

Alongside the exhibiting of Barbara and Peter, Auckland Museum has made public the preliminary scientific research on the specimens, undertaken by expert academics.

These preliminary reports have been prepared by two of the world’s top theropod palaeontologists from University of Kansas Biodiversity Institute and Natural History Museum, Dr David Burnham; and Department of Earth and Environmental Sciences, University of Manchester, Dr John Nudds, who studied both Barbara and Peter in their university laboratories for many months.

This unique display, together with published research, has afforded the public to gain a deeper understanding of the history and mysteries of the T. rex, providing insights into their origins, lives, and the remarkable process of finding and mounting fossil specimens.

— BERNAMA

KUALA LUMPUR, Nov 30 (Bernama) — Wella Company, an innovative global leader in the beauty industry marked its third year as an independent company, demonstrating broad-based growth balanced across brands, categories and geographies.

Wella Company achieved high single-digit growth in constant currency in fiscal year 2023 (FY23), which closed at the end of June, cementing its foothold as one of the fastest-growing companies in the sector.

“Looking at 2023, we are beginning to realise the benefits of the successful brand transformations across our portfolio and breakthrough innovations. We are also seeing our business mature and expand across channels and markets.

“In fiscal year 23, we grew our top line and profitability and expanded our market share, and we expect fiscal year 2024 will continue that growth trajectory,” said its Chief Executive Officer, Annie Young-Scrivner in a statement.

Continuing on the success of its leading professional hair colour brand, Koleston Perfect (KP), which sold 1.5 tubes per second globally in FY23, the company has established its professional colour credential as the No. 1 Salon Color Brand in the World, and continues to invest behind elevating its core through expansion into hair care, as well as across the nail and beauty tech portfolio.

The company has also grown its eCommerce sales at a rate of more than twice the market growth by increasing partnerships with top eComm retailers, investing in digital-first brand building, and consistently improving user experience on its owned eComm platform WellaStore to meet the needs of salon professionals.

Since its inception in 2020, Wella Company has reported year-over-year growth in both developed and emerging markets with portfolio of iconic professional and retail hair, nail, and beauty tech brands including Wella Professionals, O·P·I, ghd, Briogeo and Nioxin.

The company’s innovations touted patented technology in several areas, while continuing to elevate the look and experience of its brand portfolio, which include launching a revolutionary hair product innovations combining both speed and performance results, in addition to refreshed its packaging across its haircare line, including shampoos and conditioners, contributing to driving double-digit revenue growth globally.

Meanwhile, addressing the growing trend in scalp care, the company introduced two top-performing entrants into the space including Nioxin Ultimate Power Serum, a highly effective leave-on scalp treatment designed to strengthen hair from the root and increase hair anchorage.

It also issued Environmental and Social Impact Report 2022, the first measured analysis of its efforts to positively impact People, Planet and through its Products with key highlights include a broad-based employee ownership programme, and committed to reducing carbon footprint as well as water use and waste.

— BERNAMA

KUALA LUMPUR, Dec 1 (Bernama) — Malaysia has now over 2,200 sponsored clinical research conducted since 2012, with over 25,000 trial participants in these studies across different therapeutic areas, according to recent data inferred by Clinical Research Malaysia (CRM). Clinical Research Malaysia is a Global Trusted Research Management Organisation by the Ministry of Health that was given the mandate to catalyze sponsored research in the nation through building a robust clinical research ecosystem.

Clinical research has always been at the forefront of drug development and emerging innovative therapies. The Government of Malaysia recognized the value of clinical trials and has since built clinical research as an agenda within its 2010 National Economic Plan, lending to the establishment of CRM. The aim is to enable a facilitative ecosystem for global institutions (eg: pharmaceuticals, medical device companies and biotechnology companies) as well as the local industry to conduct clinical research in Malaysia.

The expansion of clinical research since CRM’s formation has been especially impactful to patients enrolled in these studies. Close to 30% of the studies that were conducted in Malaysia are in cancer, cardiovascular diseases, and diabetes, which coincidentally are also the top three non-communicable diseases in Malaysia. Most importantly, these studies help address the unmet needs of the trial participants, especially in having early access to innovative investigative therapies when all other treatment options have been exhausted.

The scope of patients that have access to these trials has been cast wide with many of the tertiary public hospitals, university hospitals and several private centers having clinical research conducted by respective institutions’ clinicians. “As all medical procedures and clinical care of trial participants within sponsored clinical research are funded by the study sponsor, sponsored clinical research is also viewed as means that could help alleviate healthcare burden of the institution,” added Dr Ros Suzanna Ahmad Bustamam (Head of Oncology & Radiotherapy Department in Hospital Kuala Lumpur and Head of Oncology & Radiotherapy Service in Ministry of Health) when asked about the added value of clinical research.

The growth of global clinical research in Malaysia have been consistent since the establishment of CRM, especially with the last 4 years showing surplus growth annually. Just last month, CRM announced the highest record of new trials in Malaysia, breaking prior years’ achievements with 245 clinical research approved by ethics committees in year 2023 alone. Championing humanity as its principle, CRM has been in the forefront in improving access of clinical trials into Malaysia through global engagements. Activities in the past months saw CRM’s engagements during ESMO (European Society for Medical Oncology) Congress that was held at Madrid, Global Partners Consultation program by Princess Margaret Cancer Centre in Canada, Regional Asian Clinical Trial Annual (REACTA) Forum in Chiba, Japan and Clinical Research Governance World Conference in Hong Kong, all aimed towards bringing impactful trials to Malaysia in addition to exploring collaborations that would further enhance Malaysia’s clinical research capabilities, especially in early phase clinical research.

Besides the intangible benefit of addressing unmet needs of Malaysian patients, clinical research has also significantly contributed over RM 1 billion in Gross National Income since 2012 and created over 2600 new skilled jobs in clinical research within the country. These coupled with Malaysia’s track record for having delivered consistent performance in global clinical research through speed, quality & reliability has positioned the country as a strategic clinical research hub within the region.  

About Clinical Research Malaysia (CRM)
Clinical Research Malaysia (CRM) is a Global Trusted Research Management Organisation established by the Ministry of Health Malaysia in 2012. The organisation is guided by the principles of Humanity, Stability and Sustainability in providing global clinical trial solutions and enabling a thriving clinical research ecosystem in the country. At its very core, CRM aims to bring clinical research that addresses the unmet needs of patients and transforms health outcomes in Malaysia.

CRM delivers sponsored clinical trials with Speed, Reliability and Quality through operational excellence and working with stakeholders by providing end-to-end clinical research support services. Certified with both ISO 9001:2015 (Quality Management System) and ISO 37001:2016 (Anti-Bribery Management System), and being aligned to international regulations, our core values and code of conduct are ingrained throughout CRM. The strength of this organisation lies in the people of CRM as we strive in our vision to make Malaysia the preferred clinical research hub in Asia.

SOURCE : Clinical Research Malaysia (CRM)

FOR MORE INFORMATION, PLEASE CONTACT:
Name: Asha Thanabalan
Tel: +6012- 364 8043 | +603-7931 5566 (ext. 122)   
Email: asha@clinicalresearch.my  

–BERNAMA